The trial “A Research Study to See How Semaglutide Works Compared to Placebo in People with Type 2 Diabetes and Chronic Kidney Disease” (FLOW) is the first GLP-1 RA trial to primarily examine renal outcomes in participants with CKD and T2D. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.